Filing Details
- Accession Number:
- 0001140361-17-021014
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-05-16 16:54:41
- Reporting Period:
- 2017-05-15
- Filing Date:
- 2017-05-16
- Accepted Time:
- 2017-05-16 16:54:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1444380 | Nevro Corp | NVRO | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1417976 | H Andrew Galligan | C/O Nevro Corp. 1800 Bridge Parkway Redwood City CA 94065 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-05-15 | 7,500 | $3.60 | 19,333 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-05-15 | 3,496 | $74.69 | 15,837 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-05-15 | 2,698 | $75.55 | 13,139 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-05-15 | 1,306 | $76.40 | 11,833 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-05-15 | 7,500 | $0.00 | 7,500 | $3.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 44,546 | 2021-09-28 | No | 4 | M | Direct |
Footnotes
- Includes 6,833 restricted stock units.
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $73.96 to $74.94, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.02 to $75.97, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $76.02 to $76.83, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 100% of the shares subject to the option are fully vested and exercisable.
Billionaire Hedge Funds
